Evans D L, Burnett G B, Nemeroff C B
Am J Psychiatry. 1983 May;140(5):586-9. doi: 10.1176/ajp.140.5.586.
The authors administered the dexamethasone suppression test (DST) to 47 inpatients on a clinical, nonresearch psychiatric unit who had been diagnosed according to DSM-III. Of the 30 patients with major depression, 23 (77%) exhibited nonsuppression (serum cortisol concentrations greater than 5 micrograms/dl); only 1 of the 17 patients with other diagnoses and depressive symptoms exhibited nonsuppression. There was no difference in the rate of nonsuppression between the patients with subgroups of major depression, but those with major depression and psychosis had significantly higher postdexamethasone cortisol levels than those with major depression with and without melancholia and those with diagnoses other than major depression.
作者对临床非研究性精神科病房的47名根据《精神疾病诊断与统计手册》第三版（DSM - III）确诊的住院患者进行了地塞米松抑制试验（DST）。在30名重度抑郁症患者中，23名（77%）表现出抑制不足（血清皮质醇浓度大于5微克/分升）；在17名有其他诊断及抑郁症状的患者中，只有1名表现出抑制不足。重度抑郁症各亚组患者的抑制不足率无差异，但伴有精神病性症状的重度抑郁症患者地塞米松给药后的皮质醇水平显著高于伴有或不伴有 melancholia的重度抑郁症患者以及非重度抑郁症诊断的患者。
